MedEdTalks - Hematology
5 episodes - English - Latest episode: over 3 years ago -MedEdTalks Hematology is an accredited educational podcast for providers to learn more about treating patients with Hematology diseases/disorders. Discover all content and topics by visiting mededtalks.com.
Homepage Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
Harnessing Shared Decision-making in Patients With Hemophilia A With Regina Butler, RN-BC and Courtney Thornburg, MD
November 25, 2020 00:42 - 13 minutes - 6.03 MBIn this podcast, expert clinicians review strategies to engage patients with hemophilia A in their own care to improve overall patient satisfaction.
Communicating With Patients for Optimized Hemophilia A Care With Regina Butler, RN-BC and Patient Advocate, Charles Felthaus
November 25, 2020 00:40 - 13 minutes - 6.25 MBIn this podcast, a clinician and patient discuss his experience with hemophilia A, addressing patient concerns regarding this condition, its management, and preferred communication methods.
New Treatment Options to Overcome Challenges in Hemophilia A Management With Regina Butler, RN-BC and Michael Callaghan, MD
November 25, 2020 00:38 - 14 minutes - 6.47 MBIn this podcast, expert clinicians discuss recent and emerging treatment options with the potential to benefit patients with and without inhibitors.
V:\Activity\Hematology_Oncology\2020\2020 Genentech Hemophilia A Podcast Series_K255\2020 Genentech Hemophilia A Podcast Series Web-K255\Deliverables\Final Audio Files\K255 WITHOUT INTROS
November 25, 2020 00:22 - 15 minutes - 6.86 MBIn this podcast, expert clinicians discuss historical challenges in hemophilia A care and how recent therapeutic advancements help to overcome these limitations.
Hemophilia A: Incorporating New Therapeutic Strategies to Address Historical Treatment Challenges
November 24, 2020 14:44 - 1 minute - 525 KBHemophilia A is an X-linked recessive disease primarily affecting males. An estimated 20,000 individuals in the United States have the disease. Conventional standard of care for patients with severe disease is factor VIII administration given prophylactically or to treat bleeding episodes. Almost 30% of patients treated with factor VIII develop neutralizing antibodies known as inhibitors, which require treatment with expensive bypassing agents. Newer approaches to treating hemophilia A inclu...